

**AL DHAFRA INSURANCE  
COMPANY P.S.C.**

**Review report and interim  
financial information  
for the nine months period  
ended 30 September 2017**

# **AL DHAFRA INSURANCE COMPANY P.S.C.**

## **Review report and interim financial information for the nine months period ended 30 September 2017**

|                                                                             | <b>Pages</b>  |
|-----------------------------------------------------------------------------|---------------|
| <b>The Board of Directors' Report</b>                                       | <b>1</b>      |
| <b>Report on review of interim financial information</b>                    | <b>2</b>      |
| <b>Condensed statement of financial position</b>                            | <b>3</b>      |
| <b>Condensed statement of profit or loss</b>                                | <b>4</b>      |
| <b>Condensed statement of profit or loss and other comprehensive income</b> | <b>5</b>      |
| <b>Condensed statement of changes in equity</b>                             | <b>6</b>      |
| <b>Condensed statement of cash flows</b>                                    | <b>7</b>      |
| <b>Notes to the condensed financial statements</b>                          | <b>8 – 23</b> |


**The Board of Directors' Report  
for the nine months period ended 30 September 2017**

The Board of Directors takes pleasure in presenting the unaudited results for the nine months period ended 30 September 2017.

As noted below, net underwriting income increased by AED 18,025,319 and profit for the period has increased by AED 12,184,996 as compared to the same period in the prior year.

| Particulars                                          | 9 months ended 30 September                |                                         |
|------------------------------------------------------|--------------------------------------------|-----------------------------------------|
|                                                      | 2017                                       | 2016                                    |
|                                                      | AED<br>(unaudited)                         | AED<br>(unaudited)                      |
| Gross written premium                                | 331,890,319                                | 271,154,642                             |
| Net underwriting income                              | 44,364,620                                 | 26,339,301                              |
| General, administrative and other operating expenses | (25,270,120)                               | (23,198,044)                            |
| Income from investments and investment properties    | 19,009,515                                 | 22,732,913                              |
| Profit for the period                                | 38,784,864                                 | 26,599,868                              |
| Basic and diluted earnings per share (AED)           | 0.39                                       | 0.27                                    |
|                                                      | 30 September<br>2017<br>(unaudited)<br>AED | 31 December<br>2016<br>(audited)<br>AED |
| Shareholders' equity                                 | 335,551,246                                | 310,960,478                             |
| Total assets                                         | 1,083,732,367                              | 1,013,906,843                           |

On behalf of the Board of Directors



**Chairman**

05 NOV 2017



## REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

To the Board of Directors of  
Al Dhafra Insurance Company P.S.C.  
Abu Dhabi  
United Arab Emirates

### *Introduction*

We have reviewed the accompanying condensed statement of financial position of Al Dhafra Insurance Company P.S.C. (the "Company") as of 30 September 2017 and the related condensed statements of profit or loss, profit or loss and other comprehensive income, changes in equity and cash flows for the nine-month period then ended. Management of the Company is responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard IAS 34, "*Interim Financial Reporting (IAS 34)*". Our responsibility is to express a conclusion on this interim financial information based on our review.

### *Scope of review*

We conducted our review in accordance with International Standard on Review Engagements 2410, "*Review of Interim Financial Information performed by the Independent Auditor of the Entity*". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### *Conclusion*

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with IAS 34.

Deloitte & Touche (M.E.)



Signed by:  
Rama Padmanabha Acharya  
Registration No. 701

**05 NOV 2017**

Abu Dhabi  
United Arab Emirates

**Condensed statement of financial position  
at 30 September 2017**

|                                                                               | Notes | 30 September 2017<br>AED<br>(unaudited) | 31 December 2016<br>AED<br>(audited) |
|-------------------------------------------------------------------------------|-------|-----------------------------------------|--------------------------------------|
| <b>ASSETS</b>                                                                 |       |                                         |                                      |
| Property and equipment                                                        |       | 834,015                                 | 1,052,616                            |
| Investment properties                                                         | 5     | 82,000,000                              | 82,000,000                           |
| Intangible assets                                                             |       | 1,383,979                               | 2,075,313                            |
| Statutory deposit                                                             | 6     | 10,000,000                              | 10,000,000                           |
| Deferred acquisition costs                                                    |       | 21,838,624                              | 8,825,995                            |
| Investments at amortised cost                                                 | 7     | 8,002,739                               | 8,002,739                            |
| Investments carried at fair value through other comprehensive income (FVTOCI) | 7     | 184,086,127                             | 183,280,223                          |
| Investments carried at fair value through profit or loss (FVTPL)              | 7     | 94,455,602                              | 93,382,832                           |
| Insurance receivables                                                         | 8     | 108,681,555                             | 105,546,223                          |
| <i>Reinsurers' share of technical provisions</i>                              | 9     |                                         |                                      |
| Unearned premium reserve                                                      |       | 135,990,313                             | 85,709,080                           |
| Claims under settlement reserve                                               |       | 127,030,872                             | 153,355,517                          |
| Claims incurred but not reported reserve                                      |       | 49,687,625                              | 44,956,586                           |
| Unexpired risk reserve                                                        |       | 1,838,360                               | 2,947,416                            |
| Other receivables and prepayments                                             |       | 8,818,974                               | 6,938,253                            |
| Term deposits                                                                 | 10    | 230,560,304                             | 195,693,832                          |
| Cash and cash equivalents                                                     | 10    | 18,523,278                              | 30,140,218                           |
| <b>Total assets</b>                                                           |       | <b>1,083,732,367</b>                    | <b>1,013,906,843</b>                 |
| <b>EQUITY AND LIABILITIES</b>                                                 |       |                                         |                                      |
| <b>Capital and reserves</b>                                                   |       |                                         |                                      |
| Share capital                                                                 | 12    | 100,000,000                             | 100,000,000                          |
| Legal reserve                                                                 | 13    | 50,000,000                              | 50,000,000                           |
| General reserve                                                               | 13    | 145,000,000                             | 145,000,000                          |
| Investment revaluation reserve                                                |       | (8,315,621)                             | (9,121,525)                          |
| Retained earnings                                                             |       | 48,866,867                              | 25,082,003                           |
| <b>Total equity</b>                                                           |       | <b>335,551,246</b>                      | <b>310,960,478</b>                   |
| <b>Liabilities</b>                                                            |       |                                         |                                      |
| Provision for employees' end of service benefit                               |       | 6,973,462                               | 7,998,361                            |
| Other payables                                                                | 14    | 17,407,662                              | 26,318,602                           |
| <i>Insurance liabilities</i>                                                  |       |                                         |                                      |
| Insurance payables                                                            | 15    | 198,195,364                             | 166,043,585                          |
| Unearned commission income                                                    |       | 34,671,291                              | 19,296,732                           |
| <i>Gross technical provisions</i>                                             | 9     |                                         |                                      |
| Unearned premium reserve                                                      |       | 199,599,365                             | 146,593,104                          |
| Claims under settlement reserve                                               |       | 202,607,382                             | 258,738,492                          |
| Claims incurred but not reported reserve                                      |       | 81,477,663                              | 69,457,819                           |
| Unallocated loss adjustment expense                                           |       | 5,211,003                               | 5,552,254                            |
| Unexpired risk reserve                                                        |       | 2,037,929                               | 2,947,416                            |
| <b>Total liabilities</b>                                                      |       | <b>748,181,121</b>                      | <b>702,946,365</b>                   |
| <b>Total equity and liabilities</b>                                           |       | <b>1,083,732,367</b>                    | <b>1,013,906,843</b>                 |



Assistant General Manager - Finance



General Manager



Board Member

The accompanying notes form an integral part of these condensed financial statements.

**Condensed statement of profit or loss  
for the nine months period ended 30 September 2017**

|                                                    | Notes | 3 months ended 30 September |                            | 9 months ended 30 September |                            |
|----------------------------------------------------|-------|-----------------------------|----------------------------|-----------------------------|----------------------------|
|                                                    |       | 2017<br>AED<br>(unaudited)  | 2016<br>AED<br>(unaudited) | 2017<br>AED<br>(unaudited)  | 2016<br>AED<br>(unaudited) |
| Gross written premium                              |       | 86,765,397                  | 72,496,368                 | 331,890,319                 | 271,154,642                |
| Reinsurance premium ceded                          |       | (58,036,125)                | (45,585,702)               | (228,675,889)               | (158,338,426)              |
| Reinsurance share of ceded business premium        |       | (718,627)                   | (900,886)                  | (2,405,752)                 | (4,436,622)                |
| <b>Net premium</b>                                 |       | <b>28,010,645</b>           | <b>26,009,780</b>          | <b>100,808,678</b>          | <b>108,379,594</b>         |
| Net transfer to unearned premium reserve           |       | 428,455                     | 3,621,508                  | (2,725,028)                 | 14,206,802                 |
| <b>Net premium earned</b>                          |       | <b>28,439,100</b>           | <b>29,631,288</b>          | <b>98,083,650</b>           | <b>122,586,396</b>         |
| Gross commission earned                            |       | 17,866,082                  | 13,019,710                 | 59,770,185                  | 41,314,909                 |
| Less: commission incurred                          |       | (10,150,876)                | (5,312,583)                | (36,405,944)                | (18,396,247)               |
| Change in unearned commission income               |       | 1,607,468                   | (1,490,301)                | (15,374,559)                | (9,444,436)                |
| Change in deferred acquisition costs               |       | 680,103                     | (1,929,856)                | 13,012,629                  | 3,938,738                  |
| <b>Gross underwriting income</b>                   |       | <b>38,441,877</b>           | <b>33,918,258</b>          | <b>119,085,961</b>          | <b>139,999,360</b>         |
| <b>Gross claims incurred</b>                       |       | <b>(71,373,391)</b>         | <b>(63,942,452)</b>        | <b>(210,149,932)</b>        | <b>(201,404,270)</b>       |
| Reinsurance share of insurance claims              |       | 40,815,004                  | 17,205,625                 | 109,838,528                 | 51,165,426                 |
| Reinsurance share of ceded business claims         |       | 34,731                      | 1,755,481                  | 2,930,721                   | 6,188,828                  |
| <b>Net claims paid</b>                             |       | <b>(30,523,656)</b>         | <b>(44,981,346)</b>        | <b>(97,380,683)</b>         | <b>(144,050,016)</b>       |
| Change in provision for outstanding claims         |       | 30,834,008                  | (40,522,225)               | 56,131,110                  | (50,630,295)               |
| Change in reinsurance share for outstanding claims |       | (16,511,173)                | 48,257,950                 | (26,324,645)                | 73,044,772                 |
| Change in claims incurred but not reported reserve |       | (1,477,757)                 | (4,359,488)                | (7,288,805)                 | 1,117,188                  |
| Change in unallocated loss adjustment expense      |       | 381,571                     | (908,773)                  | 341,251                     | (1,474,708)                |
| Change in unexpired risk reserve                   |       | (68,564)                    | 2,373,642                  | (199,569)                   | 8,333,000                  |
| <b>Net claims incurred</b>                         |       | <b>(17,365,571)</b>         | <b>(40,140,240)</b>        | <b>(74,721,341)</b>         | <b>(113,660,059)</b>       |
| <b>Net underwriting income/(loss)</b>              |       | <b>21,076,306</b>           | <b>(6,221,982)</b>         | <b>44,364,620</b>           | <b>26,339,301</b>          |
| Income from investments                            | 16    | 5,364,300                   | 4,259,172                  | 16,808,055                  | 20,146,292                 |
| Income from investment properties                  |       | 676,536                     | 1,137,062                  | 2,201,460                   | 2,586,621                  |
| Other gain, net                                    |       | 269,569                     | 463,798                    | 680,849                     | 725,698                    |
| <b>Total income/(loss)</b>                         |       | <b>27,386,711</b>           | <b>(361,950)</b>           | <b>64,054,984</b>           | <b>49,797,912</b>          |
| General and administrative expenses                |       | (6,324,130)                 | (6,665,062)                | (20,616,574)                | (19,355,295)               |
| Bonus and rebates (net of reinsurance)             |       | (301,288)                   | -                          | (903,864)                   | -                          |
| Other operating expenses                           |       | (1,717,933)                 | (1,151,306)                | (3,749,682)                 | (3,842,749)                |
| <b>Profit/(loss) for the period</b>                | 17    | <b>19,043,360</b>           | <b>(8,178,318)</b>         | <b>38,784,864</b>           | <b>26,599,868</b>          |
| <b>Basic and diluted earnings/(loss) per share</b> | 18    | <b>0.19</b>                 | <b>(0.08)</b>              | <b>0.39</b>                 | <b>0.27</b>                |

The accompanying notes form an integral part of these condensed financial statements.

**Condensed statement of profit or loss and other comprehensive income  
for the nine months period ended 30 September 2017**

|                                                                                 | <b>3 months ended 30 September</b> |                    | <b>9 months ended 30 September</b> |                    |
|---------------------------------------------------------------------------------|------------------------------------|--------------------|------------------------------------|--------------------|
|                                                                                 | <b>2017</b>                        | <b>2016</b>        | <b>2017</b>                        | <b>2016</b>        |
|                                                                                 | <b>AED</b>                         | <b>AED</b>         | <b>AED</b>                         | <b>AED</b>         |
|                                                                                 | <b>(unaudited)</b>                 | <b>(unaudited)</b> | <b>(unaudited)</b>                 | <b>(unaudited)</b> |
| <b>Profit/(loss) for the period</b>                                             | <b>19,043,360</b>                  | <b>(8,178,318)</b> | <b>38,784,864</b>                  | <b>26,599,868</b>  |
| <b>Other comprehensive income:</b>                                              |                                    |                    |                                    |                    |
| <i>Items that may not to be reclassified<br/>subsequently to profit or loss</i> |                                    |                    |                                    |                    |
| Net fair value changes on investments<br>carried at FVTOCI (note 7.2)           | <b>3,838,937</b>                   | <b>7,768,620</b>   | <b>805,904</b>                     | <b>15,695,958</b>  |
| Total other comprehensive income<br>for the period                              | <b>3,838,937</b>                   | <b>7,768,620</b>   | <b>805,904</b>                     | <b>15,695,958</b>  |
| <b>Total comprehensive (loss)/income<br/>for the period</b>                     | <b>22,882,297</b>                  | <b>(409,698)</b>   | <b>39,590,768</b>                  | <b>42,295,826</b>  |

The accompanying notes form an integral part of these condensed financial statements.

**Condensed statement of changes in equity  
for the nine months period ended 30 September 2017**

|                                                   | Share<br>capital<br>AED | Legal<br>reserve<br>AED | General<br>reserve<br>AED | Investment<br>revaluation<br>reserve<br>AED | Retained<br>earnings<br>AED | Total<br>AED       |
|---------------------------------------------------|-------------------------|-------------------------|---------------------------|---------------------------------------------|-----------------------------|--------------------|
| Balance at 1 January 2016 (audited) – as restated | 100,000,000             | 50,000,000              | 145,000,000               | (28,580,191)                                | 3,276,864                   | 269,696,673        |
| Profit for the period                             | -                       | -                       | -                         | -                                           | 26,599,868                  | 26,599,868         |
| Other comprehensive income                        | -                       | -                       | -                         | 15,695,958                                  | -                           | 15,695,958         |
| Total comprehensive income for the period         | -                       | -                       | -                         | 15,695,958                                  | 26,599,868                  | 42,295,826         |
| <b>Balance at 30 September 2016 (unaudited)</b>   | <b>100,000,000</b>      | <b>50,000,000</b>       | <b>145,000,000</b>        | <b>(12,884,233)</b>                         | <b>29,876,732</b>           | <b>311,992,499</b> |
| Balance at 1 January 2017 (audited)               | 100,000,000             | 50,000,000              | 145,000,000               | (9,121,525)                                 | 25,082,003                  | 310,960,478        |
| Profit for the period                             | -                       | -                       | -                         | -                                           | 38,784,864                  | 38,784,864         |
| Other comprehensive income                        | -                       | -                       | -                         | 805,904                                     | -                           | 805,904            |
| Total comprehensive (loss)/income for the period  | -                       | -                       | -                         | 805,904                                     | 38,784,864                  | 39,590,768         |
| Dividend distribution (note 23)                   | -                       | -                       | -                         | -                                           | (15,000,000)                | (15,000,000)       |
| <b>Balance at 30 September 2017 (unaudited)</b>   | <b>100,000,000</b>      | <b>50,000,000</b>       | <b>145,000,000</b>        | <b>(8,315,621)</b>                          | <b>48,866,867</b>           | <b>335,551,246</b> |

The accompanying notes form an integral part of these condensed financial statements.

**Condensed statement of cash flows  
for the nine months period ended 30 September 2017**

|                                                                                 | Notes | <b>9 months ended 30 September</b> |                    |
|---------------------------------------------------------------------------------|-------|------------------------------------|--------------------|
|                                                                                 |       | <b>2017</b>                        | <b>2016</b>        |
|                                                                                 |       | <b>AED</b>                         | <b>AED</b>         |
|                                                                                 |       | <b>(unaudited)</b>                 | <b>(unaudited)</b> |
| <b>Operating activities</b>                                                     |       |                                    |                    |
| Profit for the period                                                           |       | <b>38,784,864</b>                  | 26,599,868         |
| Adjustments for:                                                                |       |                                    |                    |
| Depreciation of property and equipment                                          |       | <b>412,642</b>                     | 631,881            |
| Amortisation of intangible assets                                               |       | <b>869,925</b>                     | 998,498            |
| Income from investments and investment properties                               |       | <b>(19,009,515)</b>                | (22,732,913)       |
| Net transfer to provision for end of service benefit                            |       | <b>(1,024,898)</b>                 | 335,160            |
| <b>Operating cash flows before movements in working capital</b>                 |       | <b>20,033,018</b>                  | 5,832,494          |
| Increase in reinsurance contract assets                                         |       | <b>(27,578,571)</b>                | (138,055,309)      |
| Increase in insurance contract liabilities                                      |       | <b>7,644,257</b>                   | 93,458,550         |
| (Increase)/decrease in insurance receivables                                    |       | <b>(3,135,332)</b>                 | 298,008            |
| (Increase)/(decrease) in other receivables and prepayments                      |       | <b>(585,985)</b>                   | 1,698,104          |
| Increase in insurance payables                                                  |       | <b>32,151,779</b>                  | 13,377,386         |
| (Decrease)/increase in other payables                                           |       | <b>(8,910,940)</b>                 | 3,037,790          |
| Increase in deferred acquisition cost                                           |       | <b>(13,012,629)</b>                | (3,938,738)        |
| Increase in unearned commission income                                          |       | <b>15,374,559</b>                  | 9,444,436          |
| <b>Net cash generated/(used) from operating activities</b>                      |       | <b>21,980,156</b>                  | (14,847,279)       |
| <b>Investing activities</b>                                                     |       |                                    |                    |
| Movement in bank deposits with original maturities of greater than three months |       | <b>(34,866,472)</b>                | (33,769,876)       |
| Interest received                                                               |       | <b>5,244,440</b>                   | 4,301,957          |
| Dividends received                                                              | 16    | <b>9,422,525</b>                   | 9,841,802          |
| Net rental proceeds on investment properties                                    |       | <b>2,201,460</b>                   | 2,586,621          |
| Proceeds from disposal of investments at FVTPL                                  | 7.2   | <b>31,558,308</b>                  | 54,664,536         |
| Payment of investment expenses                                                  |       | <b>(461,676)</b>                   | (414,046)          |
| Payments for purchase of property and equipment                                 |       | <b>(194,041)</b>                   | (166,289)          |
| Payments for purchase of intangible assets                                      |       | <b>(178,591)</b>                   | (387,844)          |
| Payments for purchase of investments at FVTPL                                   | 7.2   | <b>(31,323,049)</b>                | (42,113,479)       |
| Payments for purchase of investments at FVTOCI                                  |       | -                                  | (418,946)          |
| <b>Net cash used in investing activities</b>                                    |       | <b>(18,597,096)</b>                | (5,875,564)        |
| <b>Financing activities</b>                                                     |       |                                    |                    |
| Dividends paid                                                                  |       | <b>(15,000,000)</b>                | -                  |
| <b>Decrease in cash and cash equivalents</b>                                    |       | <b>(11,616,940)</b>                | (20,722,843)       |
| Cash and cash equivalents at the beginning of the period                        |       | <b>30,140,218</b>                  | 45,307,188         |
| <b>Cash and cash equivalents at the end of the period</b>                       | 10    | <b>18,523,278</b>                  | 24,584,345         |

The accompanying notes form an integral part of these condensed financial statements.

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017**

**1 General information**

Al Dhafra Insurance Company P.S.C. (the “Company”) is a public shareholding company incorporated in Abu Dhabi by Emiri Decree No. 8 of 1979.

The Company is domiciled in the United Arab Emirates and its registered office address is P.O. Box 319, Abu Dhabi. The Company’s ordinary shares are listed on the Abu Dhabi Securities Exchange.

The Company is engaged in insurance and reinsurance of all classes of business with the exception of endowments and annuities.

**2 Application of new and revised International Financial Reporting Standards (IFRSs)**

The following new and revised IFRSs, which became effective for annual periods beginning on or after 1 January 2017, have been adopted in these condensed financial statements. The application of these revised IFRSs has not had any material impact on the amounts reported for the current and prior periods but may affect the accounting for future transactions or arrangements.

- Amendments to IAS 12 *Income Taxes* relating to the recognition of deferred tax assets for unrealised losses
- Amendments to IAS 7 *Statement of Cash Flows* to provide disclosures that enable users of financial statements to evaluate changes in liabilities arising from financing activities
- Annual Improvements to IFRS Standards 2014–2016 Cycle – Amendments to IFRS 12

**3 Summary of significant accounting policies**

**3.1 Basis of preparation**

These condensed financial statements are prepared in accordance with International Accounting Standard (IAS) 34, “*Interim Financial Reporting*” and also comply with the applicable requirements of the laws in the U.A.E. They do not include all the information required for full annual financial statements, and should be read in conjunction with the financial statements of the Company as at and for the year ended 31 December 2016. In addition, results for nine months period ended 30 September 2017 are not necessarily indicative of the results that may be expected for the financial year ending 31 December 2017.

These condensed financial statements are presented in U.A.E. Dirham (“AED”) which is functional and presentation currency of the Company.

These condensed financial statements have been prepared on the historical cost basis, except for certain financial instruments and investment properties that are measured at fair values at the end of each reporting period.

The accounting policies and methods used in the preparation of these condensed financial statements are consistent with those used in the audited annual financial statements for the year ended 31 December 2016 except for the adoption of new standards and interpretations effective 1 January 2017.

As required by the Securities and Commodities Authority (“SCA”) notification dated 12 October 2008, accounting policies related to investment properties and financial instruments as disclosed in the annual financial statements have been disclosed in paragraph 3.2 to 3.3 below.

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**3 Summary of significant accounting policies (continued)**

**3.2 Investment properties**

Investment property is the property held to earn rentals and/or for capital appreciation. Investment properties are measured initially at cost, including transaction costs. Subsequent to initial recognition, investment properties are measured at fair value. All of the Company's property interests held under operating leases to earn rentals or for capital appreciation purposes are accounted for as investment properties and are measured using the fair value model. Gains and losses arising from changes in the fair value of investment properties are included in profit or loss in the period in which they arise.

If an investment property becomes owner occupied, it is reclassified under property and equipment and its fair value at the date of reclassification becomes its cost for subsequent accounting purposes. When an item of property and equipment is transferred to investment property following a change in use, any differences arising at the date of transfer between the carrying amount of the item immediately prior to the transfer and its fair value is recognised directly in equity if it is a gain and charged to profit or loss if it is a loss.

An investment property is derecognised upon disposal or when the investment property is permanently withdrawn from use and no future economic benefits are expected from the disposal. Any gain or loss arising on derecognition of the property (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in profit or loss in the period in which the property is derecognised.

**3.3 Investment in securities**

**3.3.1 Investments at amortised cost**

Debt instruments are measured at amortised cost if both of the following conditions are met:

- the asset is held within a business model whose objective is to hold assets in order to collect contractual cash flows; and
- the contractual terms of the instrument give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Debt instruments meeting these criteria are measured initially at fair value plus transaction costs. They are subsequently measured at amortised cost using the effective interest method less any impairment.

Subsequent to initial recognition, the Company is required to reclassify debt instruments from amortised cost to FVTPL if the objective of the business model changes so that the amortised cost criteria are no longer met.

The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocating interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts through the expected life of the debt instrument, or, (where appropriate) a shorter period, to the net carrying amount on initial recognition.

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**3 Summary of significant accounting policies (continued)**

**3.3 Investment in securities (continued)**

**3.3.2 Investments at fair value through profit and loss (FVTPL)**

Debt instrument financial assets that do not meet the amortised cost criteria described in note 3.3.1, or that meet the criteria but the entity has chosen to designate as at FVTPL at initial recognition, are measured at FVTPL. The Company has not designated a debt instrument financial asset as at FVTPL.

Subsequent to initial recognition, the Company is required to reclassify debt instruments from FVTPL to amortised cost if the objective of the business model changes so that the amortised cost criteria starts to be met and the instrument's contractual cash flows meet the amortised cost criteria. Reclassification of debt instruments designated as at FVTPL at initial recognition is not permitted.

Investments in equity instruments are mandatorily classified as at FVTPL, unless the Company designates an investment that is not held for trading as at fair value through other comprehensive income (FVTOCI) at initial recognition as described in note 3.3.3 below.

Financial assets at FVTPL are measured at fair value, with any gains or losses arising on re-measurement recognised in profit or loss. The net gain or loss recognised in profit or loss is included in the 'net investment and other income' line item in the profit and loss. Fair value is determined with reference to quoted prices.

**3.3.3 Financial assets at fair value through other comprehensive income (FVTOCI)**

At initial recognition, the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate investments in equity instruments as at FVTOCI. Designation at FVTOCI is not permitted if the equity investment is held for trading.

A financial asset is held for trading if:

- it has been acquired principally for the purpose of selling it in the near term; or
- on initial recognition it is part of a portfolio of identified financial instruments that the Company manages together and has evidence of a recent actual pattern of short-term profit-taking; or
- it is a derivative that is not designated and effective as a hedging instrument or a financial guarantee.

Investments in equity instruments at FVTOCI are initially measured at fair value plus transaction costs. Subsequently, they are measured at fair value with gains and losses arising from changes in fair value recognised in other comprehensive income and accumulated in the investments revaluation reserve. Where the asset is disposed of, the cumulative gain or loss previously accumulated in the investments revaluation reserve is not reclassified to profit or loss, but is reclassified to retained earnings.

Dividends on these investments in equity instruments are recognised in profit or loss when the Company's right to receive the dividends is established in accordance with IAS 18 *Revenue*, unless the dividends clearly represent a recovery of part of the cost of the investment. Dividends earned are recognised in profit or loss and are included in the 'income from investments line' item in the condensed statement of profit and loss.

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**4 Significant accounting judgments and key sources of estimation uncertainty**

The preparation of these condensed financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing these condensed financial statements, the significant judgments made by management in applying the Company's accounting policies, and the key sources of estimates uncertainty were the same as those were applied to the financial statements as at and for the year ended 31 December 2016.

**5 Investment properties**

|                                                                                  | <b>Abu Dhabi land<br/>and building<br/>AED</b> | <b>Al Ain land<br/>and building<br/>AED</b> | <b>Total<br/>AED</b> |
|----------------------------------------------------------------------------------|------------------------------------------------|---------------------------------------------|----------------------|
| Fair value as at 30 September 2017 (unaudited)<br>and 31 December 2016 (audited) | <b>69,500,000</b>                              | <b>12,500,000</b>                           | <b>82,000,000</b>    |

The plots of land in Abu Dhabi and Al Ain on which investment properties are constructed were awarded to the Company free of cost by the Executive Council of the Government of Abu Dhabi on 21 June 1981 and 27 August 1983, respectively.

The Company assesses the fair value of investment property annually and engaged external experts to estimate the fair values as at 31 December 2016. The Company assessed that those fair values have not significantly changed as at the reporting date.

The valuers have appropriate qualifications and recent experience in the valuation of properties in the relevant locations.

The fair values were determined based on the capitalisation of net income method, where the market rentals of all lettable units of the properties are assessed by reference to the rentals achieved in the lettable units as well as other lettings of similar properties in the neighbourhood. The capitalisation rate adopted is made by reference to the yield rates observed by the valuer for similar properties in the locality and adjusted based on the valuer's knowledge of the factors specific to the respective properties. In estimating the fair value of the properties, the highest and best use of the properties is their current use.

The Company occupies three floors of the building for its Head Office in Abu Dhabi with the remaining fourteen floors available for letting to third parties. For Al Ain Building, the Company is utilizing the first and mezzanine floors for housing its Al Ain Branch office with the remaining space available for letting to third parties.

Details of the Company's investment properties and information about the fair value hierarchy as at the reporting date are as follows:

|                                                                         | <b>Level 1<br/>AED</b> | <b>Level 2<br/>AED</b> | <b>Level 3<br/>AED</b> |
|-------------------------------------------------------------------------|------------------------|------------------------|------------------------|
| <b>30 September 2017 (unaudited)<br/>and 31 December 2016 (audited)</b> |                        |                        |                        |
| Investment properties in the UAE                                        | -                      | -                      | <b>82,000,000</b>      |

The investment properties are classified as Level 3 in the fair value hierarchy. There were no transfers between Level 1 and 2 or to level 3 during current and previous year.

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**6 Statutory deposit**

In accordance with the requirements of Federal Law No.6/2007, concerning the formation of the U.A.E. Insurance Authority, the Company maintains a bank deposit of AED 10,000,000 (31 December 2016: AED 10,000,000) which cannot be utilised without the consent of the U.A.E. Insurance Authority.

**7 Investments**

**7.1 Composition of investments**

|                                      | <b>30 September<br/>2017<br/>AED<br/>(unaudited)</b> | <b>31 December<br/>2016<br/>AED<br/>(audited)</b> |
|--------------------------------------|------------------------------------------------------|---------------------------------------------------|
| <b>Investments carried at FVTOCI</b> |                                                      |                                                   |
| Quoted UAE equity securities         | <b>184,086,127</b>                                   | 183,280,223                                       |
| <b>Investments carried at FVTPL</b>  |                                                      |                                                   |
| Quoted UAE equity securities         | <b>28,690,632</b>                                    | 27,558,408                                        |
| Quoted debt securities               | <b>65,764,970</b>                                    | 65,824,424                                        |
|                                      | <b>94,455,602</b>                                    | 93,382,832                                        |
| Investments at amortised cost        | <b>8,002,739</b>                                     | 8,002,739                                         |

**7.2 Movement in investments**

The movement in the investments is as follows:

|                                             | <b>30 September<br/>2017<br/>AED<br/>(unaudited)</b> | <b>31 December<br/>2016<br/>AED<br/>(audited)</b> |
|---------------------------------------------|------------------------------------------------------|---------------------------------------------------|
| <b>Investments at FVTOCI</b>                |                                                      |                                                   |
| Fair value at beginning of period/year      | <b>183,280,223</b>                                   | 163,402,610                                       |
| Additions during the period/year            | -                                                    | 418,947                                           |
| Net increase in fair value                  | <b>805,904</b>                                       | 19,458,666                                        |
| <b>Fair value at end of the period/year</b> | <b>184,086,127</b>                                   | 183,280,223                                       |

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**7 Investments (continued)**

**7.2 Movement in investments (continued)**

|                                                   | <b>30 September<br/>2017<br/>AED<br/>(unaudited)</b> | <b>31 December<br/>2016<br/>AED<br/>(audited)</b> |
|---------------------------------------------------|------------------------------------------------------|---------------------------------------------------|
| <b>Investments carried at FVTPL</b>               |                                                      |                                                   |
| Fair value at beginning of period/year            | <b>93,382,832</b>                                    | 101,478,339                                       |
| Additions during the period/year                  | <b>31,323,049</b>                                    | 64,952,722                                        |
| Proceeds from disposals during the period/year    | <b>(31,558,308)</b>                                  | (77,428,501)                                      |
| Loss on disposal during the period/year (note 16) | <b>(290,085)</b>                                     | (3,787,570)                                       |
| Increase in fair value (note 16)                  | <b>1,598,114</b>                                     | 8,167,842                                         |
|                                                   | <hr/>                                                | <hr/>                                             |
| <b>Fair value at end of the period/year</b>       | <b>94,455,602</b>                                    | 93,382,832                                        |
|                                                   | <hr/>                                                | <hr/>                                             |
| <b>Investment at amortised cost</b>               |                                                      |                                                   |
| Amortised cost at beginning of period/year        | <b>8,002,739</b>                                     | 6,580,278                                         |
| Reversal of impairment                            | <b>-</b>                                             | 1,422,461                                         |
|                                                   | <hr/>                                                | <hr/>                                             |
| <b>Amortised cost at end of the period/year</b>   | <b>8,002,739</b>                                     | 8,002,739                                         |
|                                                   | <hr/>                                                | <hr/>                                             |
| <br><b>8 Insurance receivables</b>                |                                                      |                                                   |
|                                                   | <b>30 September<br/>2017<br/>AED<br/>(unaudited)</b> | <b>31 December<br/>2016<br/>AED<br/>(audited)</b> |
| Due from external policyholders                   | <b>97,812,882</b>                                    | 99,480,053                                        |
| Due from related party policyholders (note 11)    | <b>1,008,717</b>                                     | 479,288                                           |
| Less: allowance for doubtful debts                | <b>(7,626,301)</b>                                   | (7,634,139)                                       |
|                                                   | <hr/>                                                | <hr/>                                             |
| Net due from policyholders                        | <b>91,195,298</b>                                    | 92,325,202                                        |
| Due from insurance companies                      | <b>13,350,032</b>                                    | 6,883,326                                         |
| Due from reinsurance companies                    | <b>4,136,225</b>                                     | 6,337,695                                         |
|                                                   | <hr/>                                                | <hr/>                                             |
|                                                   | <b>108,681,555</b>                                   | 105,546,223                                       |
|                                                   | <hr/>                                                | <hr/>                                             |

The average credit period on due from policy holders is 90 to 180 days. No interest is charged and no collateral is taken on insurance receivables.

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**8 Insurance receivables (continued)**

Movement in the allowance for doubtful debts:

|                                         | <b>30 September<br/>2017<br/>AED<br/>(unaudited)</b> | <b>31 December<br/>2016<br/>AED<br/>(audited)</b> |
|-----------------------------------------|------------------------------------------------------|---------------------------------------------------|
| Balance at beginning of the period/year | 7,634,139                                            | 6,957,479                                         |
| Charge for the period/year              | -                                                    | 676,660                                           |
| Amounts reversed                        | (7,838)                                              | -                                                 |
| Balance at end of the period/year       | <b>7,626,301</b>                                     | <b>7,634,139</b>                                  |

**9 Insurance contract liabilities and reinsurance contract assets**

|                                                    | <b>30 September<br/>2017<br/>AED<br/>(unaudited)</b> | <b>31 December<br/>2016<br/>AED<br/>(audited)</b> |
|----------------------------------------------------|------------------------------------------------------|---------------------------------------------------|
| <b>Technical provisions – Gross</b>                |                                                      |                                                   |
| Unearned premium reserve (UPR)                     | 199,599,365                                          | 146,593,104                                       |
| Claims under settlement reserve (OSLR)             | 202,607,382                                          | 258,738,492                                       |
| Claims incurred but not reported reserve (IBNR)    | 81,477,663                                           | 69,457,819                                        |
| Unallocated loss adjustment expense reserve (ULAE) | 5,211,003                                            | 5,552,254                                         |
| Unexpired risk reserve (URR)                       | 2,037,929                                            | 2,947,416                                         |
|                                                    | <b>490,933,342</b>                                   | <b>483,289,085</b>                                |
| <b>Reinsurers' share of technical provisions</b>   |                                                      |                                                   |
| Unearned premium reserve (UPR)                     | 135,990,313                                          | 85,709,080                                        |
| Claims under settlement reserve (OSLR)             | 127,030,872                                          | 153,355,517                                       |
| Claims incurred but not reported reserve (IBNR)    | 49,687,625                                           | 44,956,586                                        |
| Unexpired risk reserve (URR)                       | 1,838,360                                            | 2,947,416                                         |
|                                                    | <b>314,547,170</b>                                   | <b>286,968,599</b>                                |
| <b>Technical provisions – Net</b>                  |                                                      |                                                   |
| Unearned premium reserve (UPR)                     | 63,609,052                                           | 60,884,024                                        |
| Claims under settlement reserve (OSLR)             | 75,576,510                                           | 105,382,975                                       |
| Claims incurred but not reported reserve (IBNR)    | 31,790,038                                           | 24,501,233                                        |
| Unallocated loss adjustment expense reserve (ULAE) | 5,211,003                                            | 5,552,254                                         |
| Unexpired risk reserve (URR)                       | 199,569                                              | -                                                 |
|                                                    | <b>176,386,172</b>                                   | <b>196,320,486</b>                                |

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**10 Cash and cash equivalents**

|                                                                         | <b>30 September<br/>2017<br/>AED<br/>(unaudited)</b> | <b>30 September<br/>2016<br/>AED<br/>(unaudited)</b> |
|-------------------------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Cash on hand                                                            | 18,434                                               | 15,135                                               |
| Call accounts                                                           | 18,504,844                                           | 24,569,210                                           |
| Term deposits                                                           | 230,560,304                                          | 195,693,832                                          |
| Bank balances and cash                                                  | 249,083,582                                          | 220,278,177                                          |
| Less: deposits with original maturities of<br>greater than three months | (230,560,304)                                        | (195,693,832)                                        |
| Cash and cash equivalents                                               | 18,523,278                                           | 24,584,345                                           |

The interest rate on term deposits and call accounts with banks ranges between 0.55% and 2.75% (31 December 2016: 0.66% and 3.00%) per annum. All cash and cash equivalents are held in local banks in the United Arab Emirates.

**11 Related parties**

Related parties comprise the directors and major shareholders of the Company and those entities in which they have the ability to control or exercise significant influence in financial and operational decisions. The Company maintains balances with these related parties which arise from commercial transactions:

The following balances were outstanding at the end of the reporting period:

|                                               | <i>Nature of<br/>relationship</i> | <b>30 September<br/>2017<br/>AED<br/>(unaudited)</b> | <b>31 December<br/>2016<br/>AED<br/>(audited)</b> |
|-----------------------------------------------|-----------------------------------|------------------------------------------------------|---------------------------------------------------|
| Due from related party policyholders (note 8) | Affiliates                        | 1,008,717                                            | 479,288                                           |
| Due to related party policyholders (note 15)  | Affiliates                        | -                                                    | 16,427                                            |

Transactions with related parties during the period are as follows:

|                  | <b><u>3 months ended 30 September</u><br/>2017<br/>(unaudited)<br/>AED</b> | <b><u>2016<br/>(unaudited)<br/>AED</u></b> | <b><u>9 months ended 30 September</u><br/>2017<br/>(unaudited)<br/>AED</b> | <b><u>2016<br/>(unaudited)<br/>AED</u></b> |
|------------------|----------------------------------------------------------------------------|--------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------|
| Premiums written | 272,131                                                                    | 364,091                                    | 1,454,596                                                                  | 6,617,324                                  |
| Claims paid      | 122,009                                                                    | 10,286,302                                 | 224,500                                                                    | 23,753,826                                 |

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**11 Related parties (continued)**

The transactions with related parties are made on terms equivalent to those that prevail in arm's length transactions.

Remuneration of key management personnel:

|                          | <b>9 months ended 30 September</b> |                    |
|--------------------------|------------------------------------|--------------------|
|                          | <b>2017</b>                        | <b>2016</b>        |
|                          | <b>AED</b>                         | <b>AED</b>         |
|                          | <b>(unaudited)</b>                 | <b>(unaudited)</b> |
| Short term benefits      | <b>1,609,947</b>                   | 1,609,947          |
| Post-employment benefits | <b>81,959</b>                      | 82,126             |
|                          | <b>1,691,906</b>                   | <b>1,692,073</b>   |

The remuneration of key management personnel is based on the remuneration agreed in their employment contracts as approved by the Board of Directors.

**12 Share capital**

|                                           | <b>30 September</b> | <b>31 December</b> |
|-------------------------------------------|---------------------|--------------------|
|                                           | <b>2017</b>         | <b>2016</b>        |
|                                           | <b>AED</b>          | <b>AED</b>         |
|                                           | <b>(unaudited)</b>  | <b>(audited)</b>   |
| <b>Authorised, issued and fully paid</b>  |                     |                    |
| 100,000,000 ordinary shares of AED 1 each | <b>100,000,000</b>  | 100,000,000        |

**13 Reserves**

Legal reserve

In accordance with the U.A.E. Federal Law Number (2) of 2015 concerning Commercial Companies and the Company's Articles of Association, 10% of annual profit is to be transferred to a non-distributable legal reserve until the balance of the legal reserve equals 50% of the Company's paid up share capital. This reserve is not available for dividend distribution.

General reserve

Transfers to and from the general reserve are made at the discretion of the Board of Directors and approved by the shareholders. This reserve may be used for such purposes as they deem fit.

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**14 Other payables**

|                                    | <b>30 September<br/>2017<br/>AED<br/>(unaudited)</b> | <b>31 December<br/>2016<br/>AED<br/>(audited)</b> |
|------------------------------------|------------------------------------------------------|---------------------------------------------------|
| Dividend payable                   | <b>6,050,344</b>                                     | 6,380,592                                         |
| Fee payable to insurance authority | <b>1,509,006</b>                                     | 1,484,165                                         |
| Deferred income                    | <b>1,702,432</b>                                     | 1,512,608                                         |
| Remuneration of the Directors      | -                                                    | 2,000,000                                         |
| Other payables                     | <b>8,145,880</b>                                     | 14,941,237                                        |
|                                    | <b>17,407,662</b>                                    | 26,318,602                                        |

**15 Insurance payables**

|                                    | <b>30 September<br/>2017<br/>AED<br/>(unaudited)</b> | <b>31 December<br/>2016<br/>AED<br/>(audited)</b> |
|------------------------------------|------------------------------------------------------|---------------------------------------------------|
| Due to policyholders               | <b>56,199,445</b>                                    | 36,764,970                                        |
| Due to insurance companies         | <b>40,921,458</b>                                    | 40,640,361                                        |
| Due to reinsurance companies       | <b>24,111,500</b>                                    | 31,174,892                                        |
| Due to related party policyholders | -                                                    | 16,427                                            |
| Premium reserve withheld           | <b>76,962,961</b>                                    | 57,446,935                                        |
|                                    | <b>198,195,364</b>                                   | 166,043,585                                       |

The average credit period is 60 to 90 days. The Company has financial risk management policies in place to ensure that all payables are paid within the credit time frame.

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**16 Income from investments**

|                                                           | <b>9 months ended 30 September</b> |                    |
|-----------------------------------------------------------|------------------------------------|--------------------|
|                                                           | <b>2017</b>                        | <b>2016</b>        |
|                                                           | <b>AED</b>                         | <b>AED</b>         |
|                                                           | <b>(unaudited)</b>                 | <b>(unaudited)</b> |
| Dividend income on investments at FVTOCI                  | <b>8,416,363</b>                   | 8,664,431          |
| Net interest income                                       | <b>6,539,177</b>                   | 4,301,959          |
| Increase in fair value of investments at FVTPL (note 7.2) | <b>1,598,114</b>                   | 8,751,181          |
| Dividend income on investments at FVTPL                   | <b>1,006,162</b>                   | 1,177,371          |
| Loss on disposal on investments at FVTPL (note 7.2)       | <b>(290,085)</b>                   | (3,757,065)        |
| Investment expenses                                       | <b>(461,676)</b>                   | (414,046)          |
| Reversal of impairment on investment at amortised cost    | -                                  | 1,422,461          |
|                                                           | <b>16,808,055</b>                  | 20,146,292         |

**17 Profit/(loss) for the period**

Profit/(loss) for the period is stated after charging:

|                                        | <b>3 months ended 30 September</b> |                    | <b>9 months ended 30 September</b> |                    |
|----------------------------------------|------------------------------------|--------------------|------------------------------------|--------------------|
|                                        | <b>2017</b>                        | <b>2016</b>        | <b>2017</b>                        | <b>2016</b>        |
|                                        | <b>AED</b>                         | <b>AED</b>         | <b>AED</b>                         | <b>AED</b>         |
|                                        | <b>(unaudited)</b>                 | <b>(unaudited)</b> | <b>(unaudited)</b>                 | <b>(unaudited)</b> |
| Staff costs                            | <b>5,532,919</b>                   | 4,994,600          | <b>15,615,697</b>                  | 15,077,378         |
| Depreciation of property and equipment | <b>127,874</b>                     | 203,756            | <b>412,642</b>                     | 631,881            |
| Amortisation of intangible assets      | <b>248,701</b>                     | 363,754            | <b>869,925</b>                     | 998,498            |

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**18 Earnings/(loss) per share**

Earnings/(loss) per share are calculated by dividing the profit for the period by the weighted average number of shares outstanding during the period as follows:

|                                                   | <u>3 months ended 30 September</u> |             | <u>9 months ended 30 September</u> |             |
|---------------------------------------------------|------------------------------------|-------------|------------------------------------|-------------|
|                                                   | 2017                               | 2016        | 2017                               | 2016        |
|                                                   | (unaudited)                        | (unaudited) | (unaudited)                        | (unaudited) |
| Profit/(loss) for the period (AED)                | <b>19,043,360</b>                  | (8,178,318) | <b>38,784,864</b>                  | 26,599,866  |
| Ordinary shares in issue throughout the period    | <b>100,000,000</b>                 | 100,000,000 | <b>100,000,000</b>                 | 100,000,000 |
| Basic and diluted earnings/(loss) per share (AED) | <b>0.19</b>                        | (0.08)      | <b>0.39</b>                        | 0.27        |

As of 30 September 2017 and 2016, the Company has not issued any instruments that have an impact on earnings per share when exercised.

**19 Segment information**

The Company has two reportable segments, as described below, which are the Company's strategic business units. The strategic business units are managed separately because they require different approach, technology and marketing strategies. For each of the strategic business units, the Chief Operating Decision Maker reviews internal management reports on at least a quarterly basis.

The following summary describes the two main business segments:

- Underwriting of general insurance business – incorporating all classes of general insurance such as fire, marine, motor, medical, general accident and miscellaneous.
- Investments – incorporating investments in marketable equity securities and investment funds, development bonds, term deposits with banks and investment properties and other securities.

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**19 Segment information (continued)**

**19.1 Segment revenue and results**

Information regarding the Company's reportable segments is presented below:

|                              | 9 months ended 30 September 2017 (unaudited) |                    |                   | 9 months ended 30 September 2016 (unaudited) |                    |                   |
|------------------------------|----------------------------------------------|--------------------|-------------------|----------------------------------------------|--------------------|-------------------|
|                              | Underwriting<br>AED                          | Investments<br>AED | Total<br>AED      | Underwriting<br>AED                          | Investments<br>AED | Total<br>AED      |
| Direct revenues              | 391,660,503                                  | 19,301,041         | 410,961,544       | 312,469,556                                  | 14,016,797         | 326,486,353       |
| Direct costs                 | (347,295,884)                                | (1,889,639)        | (349,185,523)     | (286,130,255)                                | (1,457,526)        | (287,587,781)     |
| Administrative expenses      | (20,616,574)                                 | -                  | (20,616,574)      | (19,355,295)                                 | -                  | (19,355,295)      |
| Depreciation expense         | (412,642)                                    | -                  | (412,642)         | (631,881)                                    | -                  | (631,881)         |
| Amortisation expense         | (869,925)                                    | -                  | (869,925)         | (998,498)                                    | -                  | (998,498)         |
| Other expenses               | (3,370,979)                                  | -                  | (3,370,979)       | (2,212,370)                                  | -                  | (2,212,370)       |
| Non-cash investment gains    | -                                            | 1,598,114          | 1,598,114         | -                                            | 10,173,642         | 10,173,642        |
| <b>Segment profit</b>        | <b>19,094,499</b>                            | <b>19,009,516</b>  | <b>38,104,015</b> | <b>3,141,257</b>                             | <b>22,732,913</b>  | <b>25,874,170</b> |
| Other income                 | -                                            | -                  | 680,849           | -                                            | -                  | 725,698           |
| <b>Profit for the period</b> | <b>19,094,499</b>                            | <b>19,009,516</b>  | <b>38,784,864</b> | <b>3,141,257</b>                             | <b>22,732,913</b>  | <b>26,599,868</b> |

Revenue reported above represents revenue generated from external customers and third parties. There were no inter-segment revenues in the nine months period ended 30 September 2017 and 2016.

The accounting policies of the reportable segments are the same as the Company's accounting policies described in note 3.

Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)

19 Segment information (continued)

19.2 Segment assets and liabilities

|                            | As at 30 September 2017 (unaudited) |                    |                      | As at 31 December 2016 (audited) |                    |                      |
|----------------------------|-------------------------------------|--------------------|----------------------|----------------------------------|--------------------|----------------------|
|                            | Underwriting<br>AED                 | Investments<br>AED | Total<br>AED         | Underwriting<br>AED              | Investments<br>AED | Total<br>AED         |
| Segment assets             | 456,104,317                         | 609,104,772        | 1,065,209,089        | 411,406,999                      | 572,359,626        | 983,766,625          |
| Unallocated assets         | -                                   | -                  | 18,523,278           | -                                | -                  | 30,140,218           |
| <b>Total assets</b>        | <b>456,104,317</b>                  | <b>609,104,772</b> | <b>1,083,732,367</b> | <b>411,406,999</b>               | <b>572,359,626</b> | <b>1,013,906,843</b> |
| Segment liabilities        | 740,330,871                         | 1,799,906          | 742,130,777          | 692,960,263                      | 1,605,510          | 694,565,773          |
| Unallocated liabilities    | -                                   | -                  | 6,050,344            | -                                | -                  | 8,380,592            |
| <b>Total liabilities</b>   | <b>740,330,871</b>                  | <b>1,799,906</b>   | <b>748,181,121</b>   | <b>692,960,263</b>               | <b>1,605,510</b>   | <b>702,946,365</b>   |
| <b>Capital expenditure</b> | <b>372,632</b>                      | <b>-</b>           | <b>372,632</b>       | <b>717,036</b>                   | <b>-</b>           | <b>717,036</b>       |

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**20 Seasonality of results**

No income of seasonal nature was recorded in profit or loss for the nine months period ended 30 September 2017 and 2016.

**21 Fair value of financial instruments**

Some of the Company's financial assets are measured at fair value at the end of each reporting period. The following table provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value into Levels 1 to 3 based on the degree to which the fair value is observable.

- **Level 1** – fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities.
- **Level 2** – fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices).
- **Level 3** – fair value measurement are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

|                             | <b>Fair value as at</b>  |                         | <b>Fair value hierarchy</b> | <b>Valuation technique</b>            |
|-----------------------------|--------------------------|-------------------------|-----------------------------|---------------------------------------|
|                             | <b>30 September 2017</b> | <b>31 December 2016</b> |                             |                                       |
| <b>Financial assets</b>     | <b>AED (unaudited)</b>   | <b>AED (audited)</b>    |                             |                                       |
| Investments at FVTOCI       | <b>184,086,127</b>       | 183,280,223             | Level 1                     | Quoted bid prices in an active market |
| – Quoted equity investments |                          |                         |                             |                                       |
| Investments at FVTPL        | <b>28,690,632</b>        | 27,558,408              | Level 1                     | Quoted bid prices in an active market |
| – Quoted equity investments |                          |                         |                             |                                       |
| Investments at FVTPL        | <b>65,764,970</b>        | 65,824,424              | Level 1                     | Quoted bid prices in an active market |
| – Quoted debt securities    |                          |                         |                             |                                       |

During the period, there were no transfers between Level 1 and Level 2 fair value measurements, and no transfers into or out of Level 3 fair value measurements.

The Company's management considers that the fair values of financial assets and financial liabilities that are not measured at fair value approximates to their carrying amounts as stated in the statement of financial position.

**Notes to the condensed financial statements  
for the nine months period ended 30 September 2017 (continued)**

**22 Contingent liabilities**

(a) Guarantees

|                 | <b>30 September<br/>2017<br/>AED<br/>(unaudited)</b> | 31 December<br>2016<br>AED<br>(audited) |
|-----------------|------------------------------------------------------|-----------------------------------------|
| Bank guarantees | <b>16,341,922</b>                                    | 16,232,922                              |

The above bank guarantees were issued in the normal course of business.

Bank guarantees include AED 10 million (31 December 2016: AED 10 million) in respect of a bank guarantee issued on behalf of the Company to the Insurance Authority of U.A.E. in accordance with the requirements of Federal Law No.6/2007, concerning the formation of the U.A.E. Insurance Authority.

(b) Legal proceedings

The Company operates in the insurance industry and is subject to legal proceedings in the normal course of business. While it is not practicable to forecast or determine the final results of all pending or threatened legal proceedings, management does not believe that such proceedings (including litigation) will have a material effect on its results and financial position.

**23 Dividend distribution**

Dividends, amounting to AED 15,000,000 for the year ended 31 December 2016, were approved by the Shareholders at the Annual General Meeting held on 21 March 2017.

**24 Approval of condensed financial statements**

These condensed financial statements were approved and authorised for issue by the Board of Directors on

05 NOV 2017.